scholarly article | Q13442814 |
P2093 | author name string | Saenko EL | |
Shima M | |||
Scandella D | |||
Rajalakshmi KJ | |||
P433 | issue | 15 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 11601-11605 | |
P577 | publication date | 1994-04-01 | |
P1433 | published in | Journal of Biological Chemistry | Q867727 |
P1476 | title | A role for the C2 domain of factor VIII in binding to von Willebrand factor | |
P478 | volume | 269 |
Q52590007 | An intronic mutation c.6430-3C>G in the F8 gene causes splicing efficiency and premature termination in hemophilia A. |
Q36447889 | Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation |
Q37382199 | B-cell and T-cell epitopes in anti-factor VIII immune responses |
Q41721581 | Binding of Factor VIII to Lipid Nanodiscs Increases its Clotting Function in a Mouse Model of Hemophilia A. |
Q42036652 | Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry. |
Q35602099 | Blood coagulation factor VIII: An overview |
Q37378510 | Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies. |
Q36742268 | Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies |
Q36621449 | Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa |
Q42213583 | FVIII-VWF dos-à-dos |
Q34055694 | Factor VIII lacking the C2 domain retains cofactor activity in vitro |
Q36317966 | Highly conserved antigenic structure of the factor VIII C2 domain in some mammals. |
Q34744656 | Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates |
Q92212325 | Interaction Between the a3 Region of Factor VIII and the TIL'E' Domains of the von Willebrand Factor |
Q41167453 | Intracellular retention of a factor VIII protein with an Arg2307-->Gln mutation as a cause of haemophilia A. |
Q35498838 | Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein |
Q36970547 | Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex |
Q37382208 | Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives |
Q41850873 | Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry |
Q92619754 | Molecular Mechanisms of Inhibitor Development in Hemophilia |
Q33962546 | Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. |
Q36835121 | Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors |
Q33954639 | Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice |
Q34688731 | Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function |
Q85025577 | Phospholipid binding improves plasma survival of factor VIII |
Q80273707 | Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain |
Q35007278 | Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody |
Q27680123 | Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes |
Q35578480 | The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces |
Q35832756 | The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies. |
Q45866649 | The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein |
Q27648918 | The tertiary structure and domain organization of coagulation factor VIII |
Search more.